Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAV680 in Seasonal Allergic Rhinitis
NCT00784732Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Primary completion
- Dec 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of QAV680 in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Novartis. Primary endpoints: Total Nasal Symptom Score at Day 10 and Percentage nasal lavage eosinophil count at Day 10. Started Sep 2008; status: completed.
02
Drugs
QAV680
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00784732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784732.